linjc16/ctgov huggingface dataset:
Comparison of Pre-operative EUS Guided and Intra-operative Direct Portal Vein Pressure Measurement in Pretransplant Cirrhotics

Study Overview
=================
Brief Summary
-----------------
Direct portal pressure measurement under EUS-guidance (EUS-PPM) is a promising alternative to conventional indirect Hepatic Venous Pressure Gradient (HVPG). In patients undergoing liver transplantation for cirrhosis, high pre-operative portal vein (PV) pressure requires intra-operative portal vein inflow modulation (PIM). This pilot study aims to assess correlation between EUS-PPM with direct intra-operative portal pressure measurement (IO-PPM).

Official Title
-----------------
Comparison of Pre-operative EUS Guided and Intra-operative Direct Portal Vein Pressure Measurement in Pretransplant Cirrhotics - Prospective Observational Study

Conditions
-----------------
Liver Cirrhosis

Intervention / Treatment
-----------------
* Procedure: EUS Portal pressure measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Liver cirrhosis patients scheduled for liver transplant for the standard indications within next 24- 48 hours will be included. Exclusion Criteria: Severe ascites not amenable for tapping History of blood thinner consumption within last 5 days Active duodenal ulcerations

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: EUS Portal pressure measurement|Direct portal pressure measurement under EUS-guidance (EUS-PPM) is a promising alternative to conventional indirect Hepatic Venous Pressure Gradient (HVPG). In patients undergoing liver transplantation for cirrhosis, high pre-operative portal vein (PV) pressure requires intra-operative portal vein inflow modulation (PIM)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between EUS-PPM with direct intra-operative portal pressure measurement (IO-PPM). | Correlation between EUS-PPM with direct intra-operative portal pressure measurement (IO-PPM). | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between readings of EUS-PPM using portable manometry set and arterial transducer. | Correlation between readings of EUS-PPM using portable manometry set and arterial transducer. | 1 year |
The Severity of Periodontitis at the Buccal and Palatal Site

Study Overview
=================
Brief Summary
-----------------
To record and compare the periodontal conditions of buccal and palatal sites in patients

Official Title
-----------------
The Comparison of the Severity of Periodontitis at the Buccal and Palatal Site

Conditions
-----------------
Periodontal Diseases

Intervention / Treatment
-----------------
* Other: No interventions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with diagnosed periodontitis Exclusion Criteria: compromised systematic health (uncontrolled hypertension, diabetes, impaired bone metabolism condition, etc.), uncontrolled periodontal disease, smoking > 20 cigarettes/day or recent chemotherapy/radiotherapy in the oral and maxillofacial regions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No interventions|No interventions|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| probing depth | the probing depth of buccal and palatal sites of teeth in one patient | 3 years |
Core Strength and Coordinative Skills

Study Overview
=================
Brief Summary
-----------------
Evaluation of healthy young adults regarding balance, core strength/core stability and physical fitness. Correlation of primary outcome parameters and selected secondary parameters.

Official Title
-----------------
Correlation of Core Strength/Core Stability and Coordinative Skills in Healthy Adults - an Explorative Study

Conditions
-----------------
Postural Balance, Core Strength, Core Stability, Physical Fitness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adequat cognitive and lingual competence Written informed consent Exclusion Criteria: low back pain or other painful disorders regarding the spine during the last 6 weeks Previous spine surgery Neurologic disease or disease of the vestibular organ Previous arthroplasty of joints

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy adults<br>Healthy adults between 18 and 35 years | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Center of pressure track (COPT) | Posturographic parameter; lower values indicate better postural stability | Baseline | 
| Area of sway (AOS) | Posturographic parameter; lower values indicate better postural stability | Baseline | 
| Core stability test of the Swiss Olympic Medical Center | Measurement of Core strength/Core stability in sec; higher values indicate better core strength | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Baecke Questionnaire of Habitual Physical Activity (BQHPA) | Questionnaire of physical fitness; higher values indicate higher physical fitness | Baseline | 
| Stability energy | Posturographic parameter, measures economy of movement; higher values mean lower stabilty | Baseline | 
| Harmony index | Posturographic parameter | Baseline | 
| Frequency of sway | Posturographic parameter | Baseline | 
| Feedback | Posturographic parameter; quantitative data; a score is calculated by the posturographic system to determine the influence of visual, vestibular and somatosensory feedback on postural control | Baseline | 
| Movement control | Posturographic parameter; the frequencies of the movement amplitude during the posturographic measurement are calculated and a score for the low and high frequencies is presented. For the lower frequencies (F1, F2) higher values are positive. For the higher frequencies (F3 - F8) lower values are positive. | Baseline | 
| Weight distribution index | Posturographic parameter; Center of pressure at beginning of measurement | Baseline | 
| Body mass index (BMI) | Relation weight to height | Baseline |
Patients With Geographic Atrophy and Their Patient Journey in the United States (US)

Study Overview
=================
Brief Summary
-----------------
To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).

Official Title
-----------------
Characterization of Patients With Geographic Atrophy (GA) in the US

Conditions
-----------------
Geographic Atrophy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - All patients ≥50 years, with a GA diagnosis in at least one eye, included in the Vestrum database identified during the study period (January 2015 to April 2023). Exclusion Criteria: - Patients without the information of laterality will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with a Geographic Atrophy diagnosis<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of developing of Neovascular Age-Related Macular Degeneration (wAMD) |  | Up to the 5th year of the follow-up period. | 
| Changes in the Geographic Atrophy (GA) lesion location |  | Up to the 5th year of the follow-up period. | 
| Changes in the Visual Acuity (VA) |  | Up to the 5th year of the follow-up period. | 
| Changes in the size of the GA lesion |  | Up to the 5th year of the follow-up period. | 
| Occurrence of developing of GA |  | Up to the 5th year of the follow-up period. | 
| Occurrence of patients with a newly diagnosis of GA |  | Up to the 5th year of the follow-up period. | 
| Prevalence of GA |  | Up to the 5th year of the follow-up period. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retinal Disease Related health care resource utilization ((HCRU) Outcome:Occurrence of patients visits |  | Up to the 5th year of the follow-up period. | 
| Retinal Disease Related HCRU Outcomes: Occurrence of medical procedures | Medical procedures include for example, checkups, cataracts removal, eye lid (ptosis correction), etc. | Up to the 5th year of the follow-up period. | 
| Occurrence of ocular comorbidities |  | Up to the 5th year of the follow-up period. |
Procalcitonin Protocol Use to Guide Antibiotic Therapy Duration in the Intensive Care Unit

Study Overview
=================
Brief Summary
-----------------
To compare and contrast antibiotic use and its effects on patient outcomes before and after the implementation of a PCT protocol in the ICU at Methodist Richardson Medical Center (MRMC).

Detailed Description
-----------------
Based on previous clinical trials, current literature supports the use of PCT levels in combination with clinical assessments to help determine optimal antibiotic therapy. On May 30, 2022, MRMC launched a PCT protocol in the ICU that allows clinical pharmacy specialists to order PCT levels in certain bacterial infections. In order to determine the effects of the protocol, a retrospective quasi-experimental review will be conducted

Official Title
-----------------
Procalcitonin Protocol Use to Guide Antibiotic Therapy Duration in the Intensive Care Unit

Conditions
-----------------
Comparing Antibiotic Duration of Therapy

Intervention / Treatment
-----------------
* Other: compare antibiotic duration of therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ● Patients aged 18 years or older Patients being monitored on the PCT protocol ICU location status for at least part of the admission Received antibiotics in the ICU for a diagnosis of: Community-acquired pneumonia Hospital-acquired pneumonia Ventilator-associated pneumonia Sepsis and/or septic shock Uncomplicated bacteremia with known source Chronic obstructive pulmonary disorder exacerbation Asthma exacerbation Exclusion Criteria: Received antibiotics in the ICU for a diagnosis of: Uncomplicated skin and soft tissue infections Abscess Empyema Bacterial infections that require prolonged antibiotic therapy (e.g., osteomyelitis, endocarditis, tuberculosis, etc.) Intra-abdominal infection Urinary tract infection Bacterial meningitis Estimated Glomerular Filtration Rate <15 mL/min Requiring renal replacement therapy Status post cardiac arrest/target temperature management

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: compare antibiotic duration of therapy|To compare antibiotic duration of therapy before and after the implementation of the PCT protocol in the ICU.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total days of antibiotic therapy | Actual antibiotic days and predicted antibiotic days (i.e., SAAR) | 6 months |
Disparities Among Liver Transplant Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to inform healthcare interventions to reduce the disparities in liver transplant listing and in transplantation.

Detailed Description
-----------------
Aim 1. Establish a longitudinal cohort of patients with end-stage liver dysfunction. Aim 2. Examine interpersonal and structural factors associated with liver transplant evaluation and listing by patient characteristics (e.g., race, ethnicity, SES, gender). Aim 3. Examine the use of stigmatizing language among patients undergoing liver transplant based on their demographic characteristics (e.g., race, ethnicity, SES, gender).

Official Title
-----------------
Individual and Structural-level Determinants Associated With Disparities Among Liver Transplant Patients

Conditions
-----------------
End Stage Liver DIsease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients with end-stage liver, kidney, or cardiac dysfunction. Exclusion Criteria: Patients with more than one system with end stage organ dysfunction, dementia, cognitive or sensory impairment, prior solid organ transplant. Patients with potential medical exclusions for transplant.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Liver Transplant Patients<br>Subjects with end-stage liver disease and being referred for transplant evaluation will fill out questionnaires about their background, emotions, and behaviors. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Liver transplant waiting list | Number of subjects listed on the liver transplant waiting list | Approximately one year | 
| Organ transplantation | Number of subject to receive an organ transplantation | Approximately one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival | Total number of subject alive | Approximately one year post-transplant, or until you are removed from the transplant list | 
| Graft survival at six months | Total number of subject to have a functioning graft at six months post transplant | Six months post transplant | 
| Graft survival at one year | Total number of subject to have a functioning graft at one year post transplant | One year post transplant | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Transplants, Transplantation, Healthcare Disparities, Minority Health, Communication
Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis

Study Overview
=================
Brief Summary
-----------------
This is a multi-center, single arm, open-label study to evaluate safety in children patients with moderate-to severe atopic dermatis.

Official Title
-----------------
A Multicenter, Single-arm, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetics of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatitis

Conditions
-----------------
Atopic Dermatitis

Intervention / Treatment
-----------------
* Biological: CM310


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: With atopic dermatis. Voluntarily sign the informed consent form. Exclusion Criteria: Any major surgery planned during the research period. With intestinal parasitic infection within the first 6 months of screening. With any previous malignant tumors prior to screening. With any circumstance that is not suitable to participate in this study.

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CM310 group A<br>CM310 injection, subcutaneous injection, once every 3 weeks. | Biological: CM310<br>* CM310 injection<br>|
| Experimental: CM310 group B<br>CM310 injection, subcutaneous injection, once every 2 weeks. | Biological: CM310<br>* CM310 injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events | Incidence of adverse events. | up to week 16 |
Evaluation of Patients With Covid-19 Infection in Terms of Severity of Osteoprosis

Study Overview
=================
Brief Summary
-----------------
Osteoporosis is a condition characterized by decreased bone strength and an increased risk of fracture. Age, gender, body mass index, fragility fracture history, corticosteroid use, immobilization, smoking and alcohol use, endocrine pathologies besides inflammatory and infectious pathologies can also be effective in the development of osteoporosis. The aim of the study is to evaluate the effect of Covid-19 infection on the development of osteoporosis. In this study, bone mineral density (BMD) measurements of patients with Covid-19 infection were examined. For this, dual-energy x-ray absorptiometry (DEXA) measurement was used. A total of 55 patients were included in the study and data such as age, height, weight, comorbidities, drugs used, and treatment methods were recorded. Results showed that the time spent in the intensive care unit was associated with the femoral neck T score in DEXA measurements of patients with Covid-19 infection. The use of drugs such as alendronate, zolendronate, denosumab or teriparatide during the treatment process did not have a statistically significant effect on the lumbar and femur T scores.

Official Title
-----------------
Kayseri City (Education and Research) Hospital

Conditions
-----------------
Severity of Osteoprosis

Intervention / Treatment
-----------------
* Other: The patients were not intervened. This is a retrospective study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female patients over the age of 18 who had dexa measurements twice before and after covid, with at least one year between two dexa measurements, and at least one month after covid infection were included in the study. Exclusion Criteria: Under the age of 18, male patients, patients with a diagnosis other than Covid-19 infection that will affect bone metabolism between the two dexa shooting dates before and after covid, patients who use another drug other than covid treatment that will affect bone metabolism between the two dexa shooting dates before and after covid not included in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: The patients were not intervened. This is a retrospective study|The patients were not intervened. This is a retrospective study|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Does the severity of osteoporosis increase in patients with Covid-19 infection? |  | 2020 August 2021 July |
Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study

Study Overview
=================
Brief Summary
-----------------
The radiotherapy scheme with extreme hypofractionation has gained space in clinical practice and, therefore, it is necessary to analyze the Brazilian national experience in selected patients with breast cancer, with the aim of evaluating the oncological outcomes and toxicities with the use of this treatment protocol.

Detailed Description
-----------------
All patients diagnosed with breast cancer who meet the eligibility criteria at participating centers will be included. Data will be collected from medical records at selected centers. Data collection will start from the location activation date. Data from up to 500 patients are expected to be collected at centers across Brazil. Patients recruited for this study will be identified at participating centers. Data on clinical, demographic and socioeconomic variables will be collected, as well as data on treatments performed and outcomes. The patient data sources will be the patients' medical records. Patients will continue to receive treatment and clinical evaluations for their illness as determined by their medical team, in accordance with the standards of care and usual clinical practice at each center. No intervention is proposed in this study.

Official Title
-----------------
Radiotherapy With Extreme Hypofractionation in Patients With Breast Cancer in Brazil: a Retrospective Cohort Study

Conditions
-----------------
Radiotherapy Side Effect

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women over 18 years old; Diagnosis of breast cancer of any molecular subtype; Undergoing extreme hypofractionated radiotherapy (5 x 5.2Gy) postoperatively; Treated from December/2019 to December/2021; With clinical and treatment data available in medical records. Exclusion Criteria: The protocol does not provide exclusion criteria.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Locoregional recurrence | To evaluate the effectiveness of the extreme hypofractionation scheme, in 5 fractions of 5.2 Gy, in women with breast cancer | 18 months |